Registry for postoperative radiochemotherapy in salivary gland cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective registry focuses on the implementation of simultaneous postoperative radiochemotherapy for patients with locally advanced high-grade salivary gland carcinoma following oncological resection. The study aims to evaluate the efficacy and tolerability of this treatment approach, which has been established in Erlangen and other locations. Eligible patients will receive guideline-compliant radiotherapy and chemotherapy regimens tailored to their specific conditions. The study will collect data on patient outcomes to better understand the impact of this combined treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Salivary gland carcinomas of the major and minor salivary glands of the head and neck region
* High-grade histology
* Successful oncological resection with curative intent
* pT3-4 or pN1-3 or Pn1(perineural sheath infiltration) or pT1-2 with scarce or positive resection margin
* cM0
* Indication for postoperative combined radiochemotherapy (guideline-compliant radiochemotherapy; percutaneous radiotherapy up to a total dose of 64-72 Gy (depending on resection status), common chemotherapy regimens: Paclitaxel 135mg/m² KOF d1 and cisplatin 33mg/m² KOF d1-3, q d22 or paclitaxel 135mg/m² KOF d1, carboplatin AUC 1.5 KOF d1-3 or paclitaxel 50mg/m² KOF, carboplatin AUC2 d1,8,15, q d22 or paclitaxel 50mg/m²KOF and cisplatin 30mg/m² KOF d1,8,15, q d22, 4 cycles each).
* Patient age ≥18 years
* WHO performance score ≤ 1
* Signed patient information/consent form

Exclusion Criteria:

* Distant metastases
* Other cancer in the last 5 years prior to study inclusion (with the exception of: adequately treated skin cancer (except melanoma) or lentigo maligno or adequately treated carcinoma in situ, in each case without evidence of active disease).
* Previous chemotherapy or radiotherapy for salivary gland carcinoma
* Previous radiotherapy in the head and neck area
* Pre-existing uncontrolled disease that constitutes a contraindication to simultaneous combination chemotherapy (e.g. signs of acute heart failure, myocardial infarction within the last 6 months before the start of therapy, congestive heart failure, heart disease with New York Heart Association (NYHA) III or IV classification, active and therapy-resistant infection, pre-existing or concomitant immunodeficiency syndrome)
* Pregnancy and breastfeeding
* Fertile patients who cannot ensure effective contraception during and up to six months after combination therapy

Where it's running

• Erlangen, Universitätsklinikum Strahlenklinik
  Erlangen, Germany Recruiting

Study contacts

• Principal investigator: Marlen Haderlein, PD Dr. — Universitätsklinikum Erlangen, Strahlenklinik
• Study coordinator: Marlen Haderlein, PD Dr.
• Email: marlen.haderlein@uk-erlangen.de
• Phone: 0913185

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Ivonescimab for advanced salivary gland cancers

  This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

• XL092 (zanzalintinib) for locally advanced or metastatic radioiodine‑refractory differentiated thyroid cancer

  This trial tests whether XL092 (zanzalintinib), an oral tyrosine kinase inhibitor, can keep radioiodine‑refractory differentiated thyroid cancer from getting worse in adults with locally advanced or metastatic disease.

  Recruiting at 2 sites Phase 2 Northwestern University · Torrance, California and 1 other locations · NCT06959641

• Using organoid testing to find effective treatments for advanced thyroid cancer

  This study tests if using lab-grown mini tumors can help find the best treatments for people with advanced thyroid cancer to improve their outcomes and lower surgery risks.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06482086

• Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma

  We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07507578

• Implantable microdevice drug screening for salivary and head and neck cancers

  This will test whether a tiny implantable microdevice can safely and quickly deliver and screen multiple cancer drugs inside salivary gland and other head and neck tumors in patients scheduled for surgical removal.

  Recruiting at 2 sites Early Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT05553782

• Abiraterone with dalpiciclib in AR-positive, HER-2 negative salivary gland cancer

  This phase 2 trial tests whether combining abiraterone and dalpiciclib helps people with AR-positive, HER-2 negative salivary gland cancer that has come back or spread.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07815522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.